Onkologie – Klimakterisches Syndrom nach Brustkrebserkrankung

• Literatur

• 1 Nelson HD. Menopause. Lancet 2008; 371: 760-70
• 2 Lester J, Pahouja G, Andersen B et al. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med 2015; 5: 50-66
• 3 Joffe H, Guthrie KA, LaCroix AZ et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014; 174: 1058-1066
• 4 Butt DA, Lock M, Lewis JE et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008; 15: 310-318
• 5 Kuiper GG, Lemmen JC, Carlsson B et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252-4263
• 6 Boucher BA, Cotterchio M, Anderson LN et al. Use of isoflavone supplements is associated with reduced postmenopausal breast cancer risk. Int J Cancer 2013; 132: 1439-1450
• 7 Tempfer CB, Hefler LA, Huber JC. Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med 2009; 122: 939-946
• 8 Druckmann RA. Non-hormonal treatment of vasomotor symptoms in female patients with and after breast carcinoma. Maturitas 2015; 81: 160
• 9 Druckmann R, Goldstein SR, Espié M. Führt Relizen^®/Femalen^®, eine nicht-hormonelle Behandlung für vasomotorische Symptome, zu einer Hemmung des CYP2D6-Enzymsystems?. Washington DC: North American Menopause Society; 2014
• 10 Grindler NM, Santoro NF. Menopause and exercise. Menopause 2015; Sep 21 [Epub ahead of print]
• 11 Huang AJ, Phillips S, Schembri M et al. Device-guided slow-paced respiration for menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2015; 125: 1130-1138
• 12 Daley A, Stokes-Lampard H, Thomas A et al. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014;
• 13 Hoeg A, Gogakos A, Murphy E et al. Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab 2012; 97: 4061-4070
• 14 Pfeiler G, Glatz C, Königsberg R et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 2011; 14: 339-344
• 15 Mueck A. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe: Anwendungsempfehlung zur Hormonsubstitution in Klimakterium und Postmenopause. Frauenarzt 2015; 56: 657-660
• 16 Ekin M, Yaşar L, Savan K et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet 2011; 283: 539-543
• 17 Tea MKM, Priemer V, Kubista E. Wirksamkeit und Sicherheit von Hyaluron-Säure-Zäpfchen (Cikatridina^®) bei der Behandlung hormon- oder chemotherapie-induzierter vaginaler Atrophie bei Mammakarzinompatientinnen. J Fertil Reprod 2006; 16: 17-19
• 18 Chen J, Geng L, Song X et al. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-croup clinical trial. J Sex Med 2013; 10: 1575-1584
• 19 Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996; 23: 259-263
• 20 Petricevic L, Unger FM, Viernstein H et al. Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet Gyn 2008; 141: 54-57